121 related articles for article (PubMed ID: 17122782)
1. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention.
Monraats PS; Kurreeman FA; Pons D; Sewgobind VD; de Vries FR; Zwinderman AH; de Maat MP; Doevendans PA; de Winter RJ; Tio RA; Waltenberger J; Huizinga TW; Eefting D; Quax PH; Frants RR; van der Laarse A; van der Wall EE; Jukema JW
Genes Immun; 2007 Jan; 8(1):44-50. PubMed ID: 17122782
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary intervention.
Monraats PS; de Vries F; de Jong LW; Pons D; Sewgobind VD; Zwinderman AH; de Maat MP; 't Hart LM; Doevendans PA; de Winter RJ; Tio RA; Waltenberger J; Frants RR; van der Laarse A; van der Wall EE; Wouter Jukema J
Pharmacogenet Genomics; 2006 Oct; 16(10):747-54. PubMed ID: 17001294
[TBL] [Abstract][Full Text] [Related]
3. The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions.
Pons D; Monraats PS; de Maat MP; Pires NM; Quax PH; van Vlijmen BJ; Rosendaal FR; Zwinderman AH; Doevendans PA; Waltenberger J; de Winter RJ; Tio RA; Frants RR; van der Laarse A; van der Wall EE; Jukema JW
Thromb Haemost; 2007 Dec; 98(6):1323-8. PubMed ID: 18064331
[TBL] [Abstract][Full Text] [Related]
4. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions.
Monraats PS; Pires NM; Agema WR; Zwinderman AH; Schepers A; de Maat MP; Doevendans PA; de Winter RJ; Tio RA; Waltenberger J; Frants RR; Quax PH; van Vlijmen BJ; Atsma DE; van der Laarse A; van der Wall EE; Jukema JW
Circulation; 2005 Oct; 112(16):2417-25. PubMed ID: 16230497
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention.
Monraats PS; Rana JS; Nierman MC; Pires NM; Zwinderman AH; Kastelein JJ; Kuivenhoven JA; de Maat MP; Rittersma SZ; Schepers A; Doevendans PA; de Winter RJ; Tio RA; Frants RR; Quax PH; van der Laarse A; van der Wall EE; Jukema JW
J Am Coll Cardiol; 2005 Sep; 46(6):1093-100. PubMed ID: 16168296
[TBL] [Abstract][Full Text] [Related]
6. The interleukin 1B-511 polymorphism is associated with the risk of developing restenosis after coronary stenting in Mexican patients.
Miranda-Malpica E; Martínez-Rios MA; Fragoso JM; Delgadillo-Rodríguez H; Rodríguez-Pérez JM; González-Quesada C; Martínez-Rodríguez N; Saldaña-Mendoza A; Peña-Duque MA; Vargas-Alarcón G
Hum Immunol; 2008 Feb; 69(2):116-21. PubMed ID: 18361937
[TBL] [Abstract][Full Text] [Related]
7. Candidate genetic markers and the risk of restenosis after coronary angioplasty.
Völzke H; Grimm R; Robinson DM; Wolff B; Schwahn C; Hertwig S; Motz W; Rettig R
Clin Sci (Lond); 2004 Jan; 106(1):35-42. PubMed ID: 12899665
[TBL] [Abstract][Full Text] [Related]
8. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions.
Rudez G; Pons D; Leebeek F; Monraats P; Schrevel M; Zwinderman A; de Winter R; Tio R; Doevendans P; Jukema W; de Maat M
Hum Mutat; 2008 Mar; 29(3):375-80. PubMed ID: 18175333
[TBL] [Abstract][Full Text] [Related]
9. p27kip1-838C>A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity.
van Tiel CM; Bonta PI; Rittersma SZ; Beijk MA; Bradley EJ; Klous AM; Koch KT; Baas F; Jukema JW; Pons D; Sampietro ML; Pannekoek H; de Winter RJ; de Vries CJ
Circulation; 2009 Aug; 120(8):669-76. PubMed ID: 19667240
[TBL] [Abstract][Full Text] [Related]
10. Relationship of interleukin-6-572C/G promoter polymorphism and serum levels to post-percutaneous coronary intervention restenosis.
Gao J; Liu Y; Cui RZ; Mao YM; Zhou J; Chen Q; Zhao FM; Yang GM
Chin Med J (Engl); 2013 Mar; 126(6):1019-25. PubMed ID: 23506572
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention.
Monraats PS; Fang Y; Pons D; Pires NM; Pols HA; Zwinderman AH; de Maat MP; Doevendans PA; DeWinter RJ; Tio RA; Waltenberger J; Frants RR; Quax PH; van der Laarse A; van der Wall EE; Uitterlinden AG; Jukema JW
Expert Opin Ther Targets; 2010 Mar; 14(3):243-51. PubMed ID: 20095921
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha plays an important role in restenosis development.
Monraats PS; Pires NM; Schepers A; Agema WR; Boesten LS; de Vries MR; Zwinderman AH; de Maat MP; Doevendans PA; de Winter RJ; Tio RA; Waltenberger J; 't Hart LM; Frants RR; Quax PH; van Vlijmen BJ; Havekes LM; van der Laarse A; van der Wall EE; Jukema JW
FASEB J; 2005 Dec; 19(14):1998-2004. PubMed ID: 16319143
[TBL] [Abstract][Full Text] [Related]
13. Fractalkine receptor polymorphisms V2491 and T280M as genetic risk factors for restenosis.
Niessner A; Marculescu R; Kvakan H; Haschemi A; Endler G; Weyand CM; Maurer G; Mannhalter C; Wojta J; Wagner O; Huber K
Thromb Haemost; 2005 Dec; 94(6):1251-6. PubMed ID: 16411402
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention.
Beijk MA; Boekholdt SM; Rittersma SZ; Pons D; Zwinderman AH; Doevendans PA; Tio RA; Tijssen JG; Jukema JW; de Winter RJ
Pharmacogenet Genomics; 2010 Sep; 20(9):544-52. PubMed ID: 20671584
[TBL] [Abstract][Full Text] [Related]
15. P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents.
Tiroch K; Koch W; Mehilli J; Bottiger C; Schomig A; Kastrati A
Cardiology; 2009; 112(4):263-9. PubMed ID: 18758183
[TBL] [Abstract][Full Text] [Related]
16. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention.
Cho HJ; Chae IH; Park KW; Ju JR; Oh S; Lee MM; Park YB
J Hum Genet; 2002; 47(2):88-91. PubMed ID: 11916008
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-10-592C/A, -819C/T and -1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients.
Ezzidi I; Mtiraoui N; Kacem M; Mallat SG; Mohamed MB; Chaieb M; Mahjoub T; Almawi WY
Clin Endocrinol (Oxf); 2009 Mar; 70(3):401-7. PubMed ID: 18616700
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory cytokine gene variants in coronary artery disease patients in Greece.
Manginas A; Tsiavou A; Chaidaroglou A; Giamouzis G; Degiannis D; Panagiotakos D; Cokkinos DV
Coron Artery Dis; 2008 Dec; 19(8):575-82. PubMed ID: 19005292
[TBL] [Abstract][Full Text] [Related]
19. Genetic risk markers for post-angioplasty restenosis: what should we expect?
Green FR
Clin Sci (Lond); 2004 Jan; 106(1):1-2. PubMed ID: 12962537
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
